Helixmith Co., Ltd (084990.KQ)
KRW 2770.0
(0.0%)
KRW 2770.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 73.55 Billion KRW | 95.72% |
| 2022 | 37.58 Billion KRW | -34.49% |
| 2021 | 57.36 Billion KRW | -70.99% |
| 2020 | 197.78 Billion KRW | 14.74% |
| 2019 | 172.37 Billion KRW | 17.87% |
| 2018 | 146.24 Billion KRW | 879.64% |
| 2017 | 14.92 Billion KRW | 110.01% |
| 2016 | 7.1 Billion KRW | 108.25% |
| 2015 | 3.41 Billion KRW | 0.0% |
| 2013 | 2.65 Billion KRW | -24.95% |
| 2012 | 3.54 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 53.29 Billion KRW | -27.55% |
| 2024 Q2 | 6.26 Billion KRW | -88.24% |
| 2023 Q1 | 35.23 Billion KRW | -6.25% |
| 2023 FY | 73.55 Billion KRW | 95.72% |
| 2023 Q4 | 73.55 Billion KRW | 153.8% |
| 2023 Q3 | 28.98 Billion KRW | -13.28% |
| 2023 Q2 | 33.42 Billion KRW | -5.15% |
| 2022 Q3 | 58.32 Billion KRW | -4.44% |
| 2022 Q2 | 61.03 Billion KRW | 2.9% |
| 2022 Q1 | 59.31 Billion KRW | 3.39% |
| 2022 FY | 37.58 Billion KRW | -34.49% |
| 2022 Q4 | 37.58 Billion KRW | -35.56% |
| 2021 Q3 | 60.56 Billion KRW | -50.28% |
| 2021 Q1 | 119.11 Billion KRW | -39.77% |
| 2021 FY | 57.36 Billion KRW | -70.99% |
| 2021 Q2 | 121.8 Billion KRW | 2.26% |
| 2021 Q4 | 57.36 Billion KRW | -5.28% |
| 2020 Q4 | 197.78 Billion KRW | 3.04% |
| 2020 Q3 | 191.94 Billion KRW | -11.77% |
| 2020 Q1 | 209.87 Billion KRW | 21.76% |
| 2020 Q2 | 217.54 Billion KRW | 3.66% |
| 2020 FY | 197.78 Billion KRW | 14.74% |
| 2019 Q1 | 179.34 Billion KRW | 22.64% |
| 2019 FY | 172.37 Billion KRW | 17.87% |
| 2019 Q4 | 172.37 Billion KRW | 18.87% |
| 2019 Q3 | 145 Billion KRW | -12.71% |
| 2019 Q2 | 166.11 Billion KRW | -7.38% |
| 2018 Q3 | 129.03 Billion KRW | 772.24% |
| 2018 Q1 | 14.56 Billion KRW | -2.42% |
| 2018 FY | 146.24 Billion KRW | 879.64% |
| 2018 Q4 | 146.24 Billion KRW | 13.33% |
| 2018 Q2 | 14.79 Billion KRW | 1.55% |
| 2017 Q4 | 14.92 Billion KRW | 0.0% |
| 2017 FY | 14.92 Billion KRW | 110.01% |
| 2016 FY | 7.1 Billion KRW | 108.25% |
| 2015 FY | 3.41 Billion KRW | 0.0% |
| 2014 Q3 | 3.09 Billion KRW | 5.05% |
| 2014 Q2 | 2.94 Billion KRW | 14.41% |
| 2014 Q1 | 2.57 Billion KRW | -3.21% |
| 2013 Q3 | 2.18 Billion KRW | -6.27% |
| 2013 Q1 | 3.66 Billion KRW | 3.62% |
| 2013 Q2 | 2.32 Billion KRW | -36.51% |
| 2013 Q4 | 2.65 Billion KRW | 21.7% |
| 2013 FY | 2.65 Billion KRW | -24.95% |
| 2012 FY | 3.54 Billion KRW | 0.0% |
| 2012 Q4 | 3.54 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | 56.597% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -3811.881% |
| BINEX Co., Ltd. | 75.68 Billion KRW | 2.812% |
| Bioneer Corporation | 80.61 Billion KRW | 8.749% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | -268.032% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | 45.808% |
| CrystalGenomics, Inc. | 97.82 Billion USD | 24.805% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 93.121% |
| Medy-Tox Inc. | 137.14 Billion KRW | 46.363% |
| Peptron, Inc. | 16.36 Billion KRW | -349.372% |
| Amicogen, Inc. | 248.12 Billion KRW | 70.355% |
| Genexine, Inc. | 79.68 Billion KRW | 7.687% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | -151.255% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | -78.188% |
| ALTEOGEN Inc. | 108.25 Billion KRW | 32.054% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | -0.644% |
| SillaJen, Inc. | 19.4 Billion KRW | -279.144% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 58.927% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | -40.139% |
| Genomictree Inc. | 7.81 Billion KRW | -841.565% |
| MedPacto, Inc. | 9.56 Billion KRW | -668.97% |
| D&D Pharmatech | 23.98 Billion KRW | -206.673% |
| EASY BIO,Inc. | 105.86 Billion KRW | 30.52% |
| GI Innovation, Inc. | 9.63 Billion KRW | -663.346% |